LAEKNA-B(02105): LAE002 has been accepted by the CDE, and a domestic AKT inhibitor is on the way.

AstraZeneca released its Q2 2026 financial report, and the oncology asset AKT inhibitor Truqap has evidently become one of its bright stars. This drug was initially underestimated at its launch (Evaluate Pharma projected a peak sales of $690 million), but now, less than three years after its market entry, it has shown a robust and steep sales curve, reaching $233 million in a single quarter by Q2 2026 and demonstrating a momentum of accelerating growth. Some overseas analysts have projected Truqap's peak sales to soar to $3 billion. Across the ocean, another potential best-in-class AKT inhibitor is gearing up. On August 11, the NDA for LAEKNA-B (02105)/Qilu Pharmaceutical's LAE002 (Afuresertib) was accepted by the CDE, and it is expected to be approved and commercialized by 2027. Its worth noting that Qilu Pharmaceutical secured exclusive rights for LAE002 in Greater China with a total maximum upfront payment and clinical development milestone payments of $530 million, positioning it among the highest in the history of drug licensing in Greater China. The alignment of "overseas blockbuster comparable products + strong investments from domestic pharmaceutical giants" makes it hard not to be optimistic about LAE002's future market potential. 01 Truqap has consistently exceeded expectations, and LAE002 will be no exception Truqap's commercial success is built on the enormous unmet clinical need in the second-line and post-line HR+/HER2- metastatic breast cancer (mBC) market. HR+/HER2- represents the largest segment in breast cancer, where the first-line standard treatment is a combination of endocrine therapy and CDK4/6 inhibitors. The issue arises after treatment resistance: after failure of CDK4/6 inhibitors, the median progression-free survival (mPFS) for patients drops drastically from over two years to the order of a few months, and this post-line market has long lacked a unified standard treatment, relying only on genetic testing to stratify and treat patients. Among these, the PAM pathway (PIK3CA/AKT1/PTEN) mutations account for about 50% of the second-line patients, which forms Truqap's target market. Breaking down the PAM pathway mutation market, there were previously no approved targeted drugs for AKT1 or PTEN mutation populations. After Truqap's launch, its market share in these two groups has approached 100%. The real competition lies with the larger PIK3CA mutation population, whose biggest competitor over the past few years has been Novartis's PI3K inhibitor Apalitinib, but in fact, Apalitinib's market share is increasingly being eroded by Truqap. Truqap's foothold in the PIK3CA population is based on a balance of efficacy and safety, particularly regarding safety. The incidence of any-grade hyperglycemia with Apalitinib is 63.7%, with grade 3 and above reaching as high as 36.6%, and nearly 40% of patients encounter severe hyperglycemia requiring medical intervention, leading some to reduce doses or discontinue treatment; in contrast, grade 3 or higher hyperglycemia with Truqap in CAPItello-291 is only 2.3%. Hyperglycemia requires ongoing monitoring of metabolic indicators, which makes clinical practitioners more willing to switch to Truqap. Truqap has successfully occupied existing market share overseas by leveraging "better tolerability," which provides a frame of reference for understanding LAE002. As a potential best-in-class molecule, LAE002 meets the conditions to support this logic across several dimensions of efficacy + safety + ease of administration. Efficacy is clearly the primary factor; the phase III AFFIRM-205 study released in April 2026 achieved strong positive top-line results, successfully meeting its primary endpointshowing statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the control group. Ease of administration determines commercial advantages; LAE002 can be administered as a continuous 125 mg daily dose, while Truqap requires 400 mg twice daily, with a regimen of four days on and three days off, clearly providing better adherence for the former. On safety, the company disclosed that patients in the AFFIRM-205 trial had good tolerability, with an extremely low discontinuation rate due to adverse events. In CAPItello-291, grade 3 and above treatment-related adverse events (TEAE) for capivasertib reached 42%, with discontinuation due to adverse events exceeding 10%. The incidence of grade 3 adverse events is significantly lower, which is an important characteristic of LAE002 as a BIC. It should be noted that the above comparisons are indirect across studies and not head-to-head, but the alignment is evident: Truqap has proven this niche market is valuable and can ramp up quickly, and LAE002 holds comparable, if not superior, data in terms of efficacy, administration methods, and tolerability, clearly laying the foundation to replicate this path in commercialization in China and global competition. 02 FDA gives the green light to CAPItello-281, opening up the large tumor market If breast cancer has determined that AKT inhibitors are on the threshold of becoming blockbusters, the FDA's approval for prostate cancer in June 2026 solidified their capability as significant drugs. On June 12, 2026, the FDA approved Truqap in combination with abiraterone and prednisone for PTEN-deficient mAPMN/S (formerly mHSPC) prostate cancer, based on phase III CAPItello-281, which demonstrated a 19% reduction in risk for radiographic progression-free survival (rPFS) (HR=0.81), extending the median rPFS from 25.7 months to 33.2 months. This marks a milestone for AKT inhibitors expanding into a second large tumor type, confirming that blocking the AKT pathway can clinical benefits beyond breast cancer. It is notable that the market potential for prostate cancer is not inferior to that of breast cancer. The incidence of PTEN loss or AKT pathway activation in prostate cancer is higher than in breast cancer, with about a quarter of mAPMN/S patients exhibiting PTEN deficiencies. Following the indication for prostate cancer, foreign investment banks have generally raised their expectations for Truqap's potential to break through the $1 billion threshold. Turning back to LAE002, its approach for prostate cancer utilizes a self-developed combination of "LAE002 + LAE001," featuring significant differentiation with advantages that can be dissected from three dimensions: mechanism, data, and market. From the mechanism perspective, LAE001 is a dual inhibitor of CYP17A1/CYP11B2, according to Frost & Sullivan data, the world's new generation of androgen synthesis inhibitors. LAE002 targets the critical resistance mechanism by blocking the AKT pathway, and the combination forms a dual attack of "androgen synthesis inhibition + pathway blockade." This combination is wholly developed by Kainos, providing stronger autonomy in patents and pipeline. From the data perspective, the phase II study LAE201 enrolled 40 patients with mCRPC who progressed after 1 to 3 lines of standard therapy (including abiraterone or second-generation AR antagonists), achieving a median rPFS of 8.1 months, representing a significant improvement compared to the historical standard treatments range of 2 to 4 months. Based on this signal, its phase III pivotal trial protocol was approved by the FDA in May 2024, representing a global registration study. From the market perspective, the prostate cancer AR pathway drug market is expanding rapidly, with the AR inhibitor market in China expected to grow from 7.2 billion yuan in 2024 to 23.9 billion yuan by 2030, with a compound annual growth rate of 22% (as estimated by securities firms). Globally, there remains a vast unmet need in the castration-resistant phase (mCRPC) post-resistance, which is precisely where LAE002 + LAE001 can make an entry. The clinical development strategies of Truqap and LAE002 should be distinctly noted. Truqap is targeting the hormone-sensitive phase (mHSPC/mAPMN/S), relatively more frontline; LAE002, on the other hand, is aimed at the castration-resistant phase (mCRPC) after ARPI treatment failure (e.g., abiraterone, enzalutamide), which is later line and harder to treat. However, the clinical development paths of both are analogous: early data generating signals, phase III protocols receiving FDA endorsement, followed by the strategy of "pushing forwards after achieving success in later lines." The success of CAPItello-281 cannot be linearly projected as a sufficient condition for LAE002's success in prostate cancer, but it is firmly established that AKT inhibitors can deliver value in prostate cancer. 03 A promising future: Domestic and global market potential stacked Just in the domestic market, the potential market space for LAE002 is quite substantial. China is one of the heaviest burdened markets for breast cancer globally, with over 350,000 new cases in 2022 and approximately 75,000 deaths. Additionally, the accessibility of biomarkers is gradually increasing: among the Chinese HR+/HER2- population, about 57% show PIK3CA/AKT1/PTEN alterations, higher than the global figure of about 50%; the risk reduction in progression or death in the CAPItello-291 Chinese cohort is 59%, also exceeding the global population's 50%. Following the patient funnel, a transparent peak value calculation can be constructed. Starting from the annual new cases of 350,000, factoring in the proportion of HR+/HER2-, late-stage metastatic cases, the percentage of second-line and above treatments, and biomarker positivity rates, the accessible pool of peak annual patients is approximately 33,000. Referring to the pricing assumption that the annual treatment cost of capivasertib is about 150,000 yuan, this corresponds to a full accessible market of about 5 billion yuan. Based on peak market shares of 25%, 50%, and 75%, the domestic peak sales for LAE002 in breast cancer can be divided into three tiers, approximately 1.25 billion yuan conservatively, 2.5 billion yuan neutrally, and 3.75 billion yuan optimistically. Even more underestimated than the domestic potential is LAE002's overseas value. Crucially, LAE002 + LAE001 is a globally registered study approved by the FDA, with Kainos assigning only the China region rights for LAE002 to Qilu, while retaining overseas rights and already having the groundwork for international multi-center clinical trials. The pricing of prostate cancer assets in the global BD market can be discerned from certain overseas cases. In February 2026, Astellas and Vir reached a global collaboration agreement on the prostate cancer asset VIR-5500, with an upfront payment of $335 million (including $240 million in cash and $75 million in equity investment) and potential milestones up to $1.37 billion, totaling up to about $1.7 billion. Notably, VIR-5500 was still in phase I at the time. Astellas was willing to commit such an early investment largely because its cooperation with Xtandi was facing patent expiration, requiring reinforcement in its prostate cancer pipeline. This indicates a strong willingness among major pharmaceutical companies to pay for prostate cancer assets, and they do not need to wait for late-phase data. LAE002 + LAE001 shares certain clear commonalities with the Astellas/Vir case: similarly targeting the large tumor type of prostate cancer and demonstrating early efficacy potential in this domain. The distinction lies in the backing of a mechanism validated by CAPItello-281 for LAE002, providing certainties that new mechanism assets lack. Before Truqap secured prostate cancer, the market hardly ever anticipated packaging LAE002 with LAE001 for overseas development. However, after the FDA greenlighted CAPItello-281, expectations around overseas opportunities are shifting positively. Conclusion: Bringing these three lines together, we need to redefine LAE002's market potential. The successful commercialization of breast cancer overseas, combined with Qilu Pharmaceuticals commitments, has already laid a solid foundation for the certainty of LAE002's domestic commercialization; the mechanism validation and global phase III clinical readiness for prostate cancer provide LAE002 with a clear second growth curve; and the gradual transition of overseas licensing expectations from 0 to something represents a substantial hidden option. $1 billion or $3 billion? Regardless, we will witness the realization and growth of this future blockbuster. This article is reproduced from Dengling Society, GMTEight editor: Feng Qiuyi.